 Brian Flynn
Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urethral Stricture | 6 | 2024 | 14 | 2.220 |
Why?
| | Urethra | 9 | 2025 | 57 | 2.030 |
Why?
| | Urinary Incontinence, Stress | 7 | 2026 | 15 | 1.790 |
Why?
| | Suburethral Slings | 2 | 2026 | 10 | 1.360 |
Why?
| | Mouth Mucosa | 5 | 2024 | 88 | 1.120 |
Why?
| | Pelvic Organ Prolapse | 2 | 2022 | 62 | 1.100 |
Why?
| | Urinary Incontinence | 5 | 2024 | 64 | 1.000 |
Why?
| | Laparoscopy | 3 | 2022 | 475 | 0.980 |
Why?
| | Urinary Bladder | 4 | 2014 | 194 | 0.860 |
Why?
| | Urinary Bladder Neck Obstruction | 3 | 2019 | 20 | 0.830 |
Why?
| | Urinary Sphincter, Artificial | 3 | 2025 | 7 | 0.770 |
Why?
| | Prostatectomy | 3 | 2024 | 93 | 0.750 |
Why?
| | Ileum | 2 | 2021 | 111 | 0.740 |
Why?
| | Urologic Surgical Procedures | 7 | 2025 | 115 | 0.690 |
Why?
| | Ureter | 1 | 2021 | 36 | 0.680 |
Why?
| | Urologic Surgical Procedures, Male | 6 | 2025 | 32 | 0.680 |
Why?
| | Ureteral Obstruction | 1 | 2021 | 62 | 0.650 |
Why?
| | Surgical Mesh | 3 | 2022 | 50 | 0.580 |
Why?
| | Vagina | 3 | 2022 | 201 | 0.580 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 182 | 0.480 |
Why?
| | Cystotomy | 1 | 2014 | 3 | 0.440 |
Why?
| | Urinary Retention | 2 | 2013 | 25 | 0.440 |
Why?
| | Urinary Catheters | 1 | 2014 | 11 | 0.440 |
Why?
| | Urinary Catheterization | 1 | 2014 | 33 | 0.430 |
Why?
| | Urinary Reservoirs, Continent | 1 | 2014 | 4 | 0.420 |
Why?
| | Treatment Outcome | 10 | 2026 | 11679 | 0.400 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2014 | 44 | 0.400 |
Why?
| | Vesicovaginal Fistula | 1 | 2013 | 5 | 0.400 |
Why?
| | Cystostomy | 1 | 2013 | 11 | 0.390 |
Why?
| | Cystoscopy | 1 | 2013 | 21 | 0.390 |
Why?
| | Constriction, Pathologic | 3 | 2024 | 248 | 0.390 |
Why?
| | Catheters | 1 | 2013 | 75 | 0.380 |
Why?
| | Retrospective Studies | 16 | 2025 | 17066 | 0.370 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2022 | 64 | 0.360 |
Why?
| | Device Removal | 1 | 2013 | 143 | 0.360 |
Why?
| | Surgical Flaps | 1 | 2013 | 142 | 0.360 |
Why?
| | Abdominal Injuries | 1 | 2013 | 127 | 0.360 |
Why?
| | Postoperative Complications | 6 | 2025 | 2919 | 0.340 |
Why?
| | Follow-Up Studies | 8 | 2025 | 5408 | 0.340 |
Why?
| | Aged | 17 | 2025 | 25913 | 0.310 |
Why?
| | Time Factors | 8 | 2025 | 7173 | 0.310 |
Why?
| | Recurrence | 5 | 2020 | 1135 | 0.300 |
Why?
| | Anastomosis, Surgical | 2 | 2014 | 157 | 0.290 |
Why?
| | Humans | 32 | 2026 | 144759 | 0.260 |
Why?
| | Middle Aged | 18 | 2025 | 35875 | 0.250 |
Why?
| | Fascia Lata | 3 | 2003 | 4 | 0.240 |
Why?
| | Male | 20 | 2026 | 72315 | 0.240 |
Why?
| | Uterine Prolapse | 2 | 2003 | 14 | 0.240 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2025 | 67 | 0.220 |
Why?
| | Reoperation | 3 | 2016 | 630 | 0.220 |
Why?
| | Peritoneal Neoplasms | 1 | 2025 | 103 | 0.210 |
Why?
| | Primary Health Care | 1 | 2014 | 1733 | 0.210 |
Why?
| | Operative Time | 2 | 2014 | 175 | 0.200 |
Why?
| | Prosthesis Failure | 2 | 2014 | 127 | 0.190 |
Why?
| | Female | 18 | 2025 | 78271 | 0.190 |
Why?
| | Cyclins | 2 | 2002 | 84 | 0.190 |
Why?
| | Pol1 Transcription Initiation Complex Proteins | 1 | 2002 | 5 | 0.190 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2002 | 49 | 0.180 |
Why?
| | Spermatic Cord Torsion | 1 | 2002 | 7 | 0.180 |
Why?
| | Urinary Tract Infections | 2 | 2014 | 202 | 0.170 |
Why?
| | Pelvic Bones | 1 | 2003 | 135 | 0.170 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2024 | 549 | 0.160 |
Why?
| | Fragile X Syndrome | 1 | 2002 | 118 | 0.160 |
Why?
| | Exophiala | 1 | 1999 | 1 | 0.150 |
Why?
| | Epididymis | 1 | 1999 | 14 | 0.150 |
Why?
| | Radiation Injuries | 1 | 2020 | 151 | 0.150 |
Why?
| | Adult | 10 | 2021 | 40449 | 0.140 |
Why?
| | Mycoses | 1 | 1999 | 88 | 0.140 |
Why?
| | Quality of Life | 2 | 2025 | 3185 | 0.140 |
Why?
| | Fractures, Bone | 1 | 2003 | 414 | 0.140 |
Why?
| | Adoptive Transfer | 1 | 2018 | 198 | 0.130 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2018 | 124 | 0.130 |
Why?
| | Urination | 2 | 2014 | 48 | 0.120 |
Why?
| | Aged, 80 and over | 4 | 2014 | 8265 | 0.110 |
Why?
| | Catheter Obstruction | 1 | 2014 | 4 | 0.110 |
Why?
| | Victoria | 2 | 2025 | 19 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2018 | 668 | 0.110 |
Why?
| | Catheters, Indwelling | 1 | 2014 | 96 | 0.100 |
Why?
| | Transcription Factors | 1 | 2002 | 1741 | 0.100 |
Why?
| | Frail Elderly | 1 | 2014 | 134 | 0.100 |
Why?
| | Fascia | 1 | 2013 | 17 | 0.100 |
Why?
| | Pelvic Pain | 1 | 2013 | 43 | 0.090 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 226 | 0.090 |
Why?
| | Blood Loss, Surgical | 1 | 2013 | 112 | 0.090 |
Why?
| | Prospective Studies | 3 | 2025 | 7990 | 0.090 |
Why?
| | Hysterectomy | 1 | 2013 | 137 | 0.090 |
Why?
| | Urodynamics | 2 | 2003 | 47 | 0.090 |
Why?
| | Ligaments | 2 | 2003 | 75 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 917 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2018 | 1129 | 0.090 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 316 | 0.090 |
Why?
| | Equipment Design | 1 | 2013 | 530 | 0.090 |
Why?
| | Colon | 1 | 2014 | 304 | 0.090 |
Why?
| | Comorbidity | 1 | 2014 | 1658 | 0.080 |
Why?
| | Adolescent | 3 | 2021 | 22428 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2009 | 292 | 0.070 |
Why?
| | Prevalence | 1 | 2014 | 2834 | 0.070 |
Why?
| | Length of Stay | 1 | 2013 | 1337 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2014 | 974 | 0.060 |
Why?
| | Antineoplastic Protocols | 1 | 2025 | 6 | 0.060 |
Why?
| | Peritoneum | 1 | 2025 | 45 | 0.060 |
Why?
| | Young Adult | 1 | 2021 | 14105 | 0.050 |
Why?
| | Prosthesis Implantation | 1 | 2025 | 153 | 0.050 |
Why?
| | Transplantation, Homologous | 2 | 2003 | 415 | 0.050 |
Why?
| | Urography | 1 | 2003 | 19 | 0.050 |
Why?
| | Perineum | 1 | 2003 | 37 | 0.050 |
Why?
| | Rupture | 1 | 2003 | 91 | 0.050 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2024 | 130 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2025 | 1266 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2002 | 55 | 0.050 |
Why?
| | Incidence | 1 | 2009 | 2879 | 0.050 |
Why?
| | Risk Factors | 1 | 2016 | 10779 | 0.050 |
Why?
| | Prostheses and Implants | 1 | 2003 | 141 | 0.040 |
Why?
| | Hypertrophy | 1 | 2002 | 127 | 0.040 |
Why?
| | Organ Size | 1 | 2002 | 463 | 0.040 |
Why?
| | Testis | 1 | 2002 | 163 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2025 | 704 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2925 | 0.040 |
Why?
| | Public Health | 1 | 2025 | 566 | 0.040 |
Why?
| | Asbestos | 1 | 1999 | 35 | 0.040 |
Why?
| | International Cooperation | 1 | 2020 | 198 | 0.040 |
Why?
| | Carcinogens | 1 | 1999 | 122 | 0.040 |
Why?
| | K562 Cells | 1 | 2018 | 93 | 0.030 |
Why?
| | Cellular Senescence | 1 | 1999 | 226 | 0.030 |
Why?
| | Proteins | 1 | 2002 | 1021 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2002 | 1499 | 0.030 |
Why?
| | Rats | 1 | 2002 | 5597 | 0.020 |
Why?
| | Cohort Studies | 1 | 2003 | 5960 | 0.020 |
Why?
| | Epithelial Cells | 1 | 1999 | 1125 | 0.020 |
Why?
| | Cytokines | 1 | 2018 | 2061 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2002 | 3863 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 851 | 0.010 |
Why?
| | Animals | 2 | 2009 | 38058 | 0.010 |
Why?
| | Urethral Obstruction | 1 | 2003 | 8 | 0.010 |
Why?
| | Valsalva Maneuver | 1 | 2003 | 10 | 0.010 |
Why?
| | Child | 1 | 2003 | 22633 | 0.010 |
Why?
| | Muscle Contraction | 1 | 2003 | 429 | 0.010 |
Why?
| | Asbestos, Amosite | 1 | 1999 | 1 | 0.010 |
Why?
| | Antigens, Polyomavirus Transforming | 1 | 1999 | 15 | 0.010 |
Why?
| | Pleural Neoplasms | 1 | 1999 | 27 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1999 | 73 | 0.010 |
Why?
| | Genes | 1 | 1999 | 226 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1999 | 112 | 0.010 |
Why?
| | Mesothelioma | 1 | 1999 | 48 | 0.010 |
Why?
| | Drug Resistance | 1 | 1999 | 153 | 0.010 |
Why?
| | Methylation | 1 | 1999 | 242 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 5992 | 0.010 |
Why?
| | Cell Division | 1 | 1999 | 766 | 0.010 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 1999 | 529 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 1999 | 1716 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1999 | 2027 | 0.010 |
Why?
| | Cell Line | 1 | 1999 | 2882 | 0.010 |
Why?
| | Mice | 1 | 2009 | 18339 | 0.010 |
Why?
| | Apoptosis | 1 | 1999 | 2430 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 1999 | 2608 | 0.000 |
Why?
|
|
Flynn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|